A recent Washington Post article underscores the growing importance of lipoprotein(a), or Lp(a)—a genetically-driven lipid that significantly raises the risk of heart attack and stroke—even in patients with normal LDL cholesterol levels. Experimental drugs such as pelacarsen and lepodisiran have shown reductions of up to 94%. Clinical trials are underway, and global screening efforts may drastically increase.
